Le Lézard
Classified in: Health

Del Rey Sinus & Allergy Institute® Innovates Again With New, Non-Invasive Treatment for Nasal Obstruction


MARINA DEL REY, Calif., June 22, 2018 /PRNewswire-PRWeb/ -- Farhad Sigari, MD, FACS, founder of Del Rey Sinus & Allergy Institute has performed the first minimally invasive nasal valve remodeling procedure in Los Angeles, and among the first offered on the West Coast. Nasal valve collapse, a significant reason for narrowing of the nasal airway, has typically been treated with over-the-counter remedies, which are never permanent and often ineffective; or traditional surgery, which involves general anesthesia and may have significant cost and extended recovery time. Now, using a low-temperature radio frequency device, Dr. Sigari can gently, permanently and immediately open patients nasal passages during a routine office visit, using only local anesthetic. Dr. Sigari performed the first procedures on three patients this week.

"Sinus specialists have not had a satisfactory toolkit to address the serious problem of nasal valve collapse," said Dr. Sigari, a board-certified otolaryngologist. "Home remedies are a conservative first step, but may only address symptoms, and traditional surgery has the obvious downsides of pain and downtime. Now we can offer our patients a fast, non-invasive choice of treatment, that can be a fix for life."

Nasal obstruction affects more than 600,000 people each year, and can greatly reduce the enjoyment of everyday activities. Whenever obstruction limits the intake of air, it can cause persistent congestion, difficulty breathing, sleep problems, snoring, fatigue from lack of sleep, and restrictions on sports and activities, among other problems. The obstruction can occur in the turbinates, the septum, or the nasal wall, which together comprise the "nasal valve." Some treatments such as medication or breathing strips can provide temporary relief of these symptoms, but do not resolve the underlying issues. Even after experiencing the pain and inconvenience of sinus surgery, some patients may have recurrence of their obstruction and the associated symptoms.

The non-invasive Vivaer nasal remodeling device uses radio frequency energy, reshaping the internal cartilage with a small wand, so that the nasal valve becomes more open and permits easier breathing. The procedure using this device can be done in-office, in 15 minutes, with only local anesthesia, and no cutting and no downtime. The procedure permanently reshapes the nasal passageway, restoring free breathing immediately, without surgery. Patients can return to their normal activities right away.

The three patients ? two male and one female ? treated by Del Rey Sinus & Allergy Institute have had previous sinus procedures, but still had difficulty breathing. Dr. Sigari notes that in all three cases the patient evidenced no discomfort and immediately experienced improved breathing. Dr. Sigari and his team will conduct follow-up exams in three to four weeks. With the addition of this procedure, Del Rey Sinus & Allergy Institute expands its range of the most advanced, minimally invasive or non-invasive techniques to sinus and allergy patients from around the world.

Clinical studies in the U.S. and European Union show that patients treated with the nasal remodeling system have experienced long-term relief, with virtually zero negative side-effects and almost 100% response rate to treatment.

About Del Rey Sinus & Allergy Institute
Part of the Del Rey MD family of clinics, Del Rey Sinus & Allergy Institute is an advanced otolaryngology medical practice. Del Rey Sinus & Allergy Institute offers a full array of the most advanced and proven techniques for accurate diagnosis and treatment of sinus and allergy conditions, including many minimally invasive or non-invasive procedures. The physicians of Del Rey MD are board-certified surgeons and Fellows of the American College of Surgeons. The practice was founded by Farhad Sigari, MD, FACS, a graduate of University of San Diego and Chicago Medical School, where he also completed surgical internship and residency. The clinics' areas of expertise include: sinusitis and sinus surgery including balloon sinus dilation; head and neck plastic surgery; snoring and sleep apnea; ear and hearing disorders including aviation and dive medicine; allergy and immunotherapy; head, neck and throat oncology; facial feminization surgery, microdermabrasion, facial masks and contouring and many other surgical and non-surgical treatments. Known for its adoption of the most innovative and advanced techniques, Del Rey MD draws patients from California, across the United States and foreign countries. Offices are located in Marina Del Rey and Bakersfield, California. For more information, visit http://www.delreysinus.com and http://www.delreymd.com.

 

SOURCE Del Rey Sinus & Allergy Institute


These press releases may also interest you

at 18:30
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...



News published on and distributed by: